DC
ENFN

Diametric Capital’s Enfusion, Inc. ENFN Stock Holding History

Diametric Capital’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,388
Closed -$206K – 450
2023
Q2 		$206K Buy
+18,388
New +$163K 0.09% 258

Other funds holding ENFN

FMC
FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Diametric Capital's ENFN Position: Q3 2023 in Review

Diametric Capital sold out of Enfusion, Inc. (ENFN) in Q3 2023, closing a stake of 18,388 shares — an estimated $206K sold.

Diametric Capital first reported a position in ENFN in Q2 2023 and held it in 1 quarter. The position peaked at $206K in Q2 2023. 75 funds tracked by Wall St. Rank hold ENFN as of Q3 2023.

  • Diametric Capital reported no remaining Enfusion, Inc. position as of Q3 2023 after selling out during the quarter.
  • Diametric Capital sold 18,388 Enfusion, Inc. shares in Q3 2023, an estimated $206K.
  • Diametric Capital first reported a position in Enfusion, Inc. in Q2 2023 and held it in 1 quarter.
  • Diametric Capital's Enfusion, Inc. position peaked at $206K in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q3 2023.

Based on Diametric Capital's 13F filing for Q3 2023, filed 14 Nov 2023.